Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

GlaxoSmithKline : Dr Hal Barron appointed Chief Scientific Officer and President, Research & Development, GSK

share with twitter share with LinkedIn share with facebook
share via e-mail
11/10/2017 | 03:31pm CEST

GlaxoSmithKline plc on November 8 announced that Dr Hal Barron has been appointed Chief Scientific Officer and President, R&D, GSK. He has also been appointed as an Executive Director to the GSK Board. Dr Barron will assume his new role and join the Board on 1 January 2018.

Dr Barron is currently President R&D at Calico (California Life Sciences LLC), an Alphabet-funded company that uses advanced technologies to increase understanding of lifespan biology. Prior to joining Calico, Dr Barron was Executive Vice President, Head of Global Product Development, and Chief Medical Officer of Roche, responsible for all the products in the combined portfolio of Roche and Genentech. At Genentech, he was Senior Vice President Development and Chief Medical Officer, according to GlaxoSmithKline.

Emma Walmsley, CEO, GSK said: Scientific innovation must be at the heart of GSK and with the appointment of Hal, we are bringing one of the worlds foremost R&D leaders to the company.

Hal has exceptional experience and a strong track record of developing significant new medicines from his time at Roche and Genentech; whilst at Calico he has helped build a research organisation that uses cutting-edge technologies in drug discovery and development. He is also very well known for his integrity, for being a clinician who is committed to always doing the best he can for patients and for building exceptional teams.

The fusion of science and technology is fast transforming pharmaceuticals R&D. With Hal, we have a new R&D leader who will drive the changes and choices we need to make to be successful in this new environment, and as we look to build the next wave of growth for the company.

Philip Hampton, Chairman, GSK, said: We are delighted that Hal will be joining GSK and look forward to welcoming him to the Board. He is a highly respected clinician-scientist with a proven ability to generate value for shareholders and his appointment reflects the Boards commitment to investing in research and development.

Dr Barron said, I am honoured to have been chosen for this important position especially given the companys renewed focus on discovering and developing transformational new medicines. GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.

During his time at Genentech and Roche, Dr Barron oversaw the development of Xolair (Asthma), Avastin (multiple tumour types), Tarceva (Lung Cancer), Lucentis (AMD), Actemra (Rheumatology), Zelboraf and Erivedge (Melanoma), Perjeta and Kadcyla (Breast Cancer), as well as Gazyva (CLL). He has overseen pioneering work in oncology, personalised medicine and has led teams across the USA, Europe and Asia.

Prior to joining Genentech as a clinical scientist in 1996, Dr Barron received his Bachelor of Science in physics from Washington University in St. Louis, his medical degree from Yale University, and completed his training in Cardiology and Internal Medicine at the University of California San Francisco.

Dr Barrons academic positions include adjunct professor at the University of California, San Francisco. He has been issued several patents for his work in thrombosis and angiogenesis and has published more than 90 papers in peer-reviewed scientific journals.

Dr Barron will be based in the US, while operating from offices in both San Francisco and Stevenage in the UK. The new office presence in San Francisco will be focused on business development for R&D.

(c) 2017 Palestine News & Information Agency (WAFA). All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

Stocks mentioned in the article
ChangeLast1st jan.
ROCHE HOLDING LTD. -0.87% 210 Delayed Quote.-14.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
06/18GLAXOSMITHKLINE : Health and Human Services Department (HHS); Food and Drug Admi..
06/18KRAFT HEINZ : WHAT A HORLICKS Malted milk drink with 145-year history now a £3bn..
06/16International fund managers turn to financials, tech as trade worries rise
06/16GLAXOSMITHKLINE : Panadol ranked as Sri Lanka's 2nd 'Most Loved Brand'
06/16GLAXOSMITHKLINE : aids Sri Pada pilgrims for ninth consecutive year
06/15Glaxo Pops But Analysts Say It`s Unlikely To Swipe Gilead Share In HIV
06/15Mylan expecting another delay for generic Advair
06/15ViiV's two-drug HIV regimen meets in Phase III for HIV
06/14GLAXOSMITHKLINE : Studies from GlaxoSmithKline plc Reveal New Findings on Medici..
06/14ADRs End Mostly Lower; iQiyi, Unilever Trade Actively
More news
News from SeekingAlpha
06/18Aptinyx Proposes Final Terms For $80 Million IPO 
06/18Global Stocks Flashing Red Over China Tariff Retaliation (Wall Street Breakfa.. 
06/18WALL STREET BREAKFAST : Trade Headwinds Blow Stronger 
06/18Epizyme Continues To Chug Along Despite FDA Partial Clinical Hold 
06/17Coca Cola considering £3B bid for GSK's Horlicks 
Financials ( GBP)
Sales 2018 29 808 M
EBIT 2018 7 924 M
Net income 2018 3 804 M
Debt 2018 19 412 M
Yield 2018 5,15%
P/E ratio 2018 20,71
P/E ratio 2019 16,78
EV / Sales 2018 3,24x
EV / Sales 2019 3,11x
Capitalization 77 170 M
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | GSK | GB0009252882 | 4-Traders
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 27
Average target price 15,6  GBP
Spread / Average Target 0,45%
EPS Revisions
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.25%328 858
PFIZER0.39%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
MERCK AND COMPANY10.24%166 880